Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 3 1Phase 1/2 1

Status

Active not recruiting 3Terminated 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Gastrointestinal 4Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Colorectal Neoplasms 10Neoplasm Metastasis 4Lung Neoplasms 4Colonic Neoplasms 4Neoplasms 3Pancreatic Neoplasms 2Carcinoma, Renal Cell 2Solid Tumors 1Resectable Non-Small Cell Lung Cancer 1Rectal Neoplasms 1Kidney Neoplasms 1Brain Neoplasms 1Biliary Tract Neoplasms 1Advanced Solid Tumor 1

Interventions

Oxaliplatin 27Fluorouracil 23Leucovorin 22Cetuximab 22Bevacizumab 21Nivolumab 16Capecitabine 16Irinotecan 15pembrolizumab 11Magnetic Resonance Spectroscopy 11Specimen Handling 10encorafenib 8Folfox protocol 7trifluridine tipiracil drug combination 6Ipilimumab 6Exercise 6fludarabine 5cemiplimab 5Trastuzumab 5Gemcitabine 5Cyclophosphamide 5Cisplatin 5Blood Specimen Collection 5Biopsy 5regorafenib 4pertuzumab 4adagrasib 4Trifluridine 4Pemetrexed 4Immune Checkpoint Inhibitors 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Colonic Neoplasms × adagrasib × 1 year × Clear all
NCT04793958 2026-04-27

KRYSTAL-10

Mirati Therapeutics Inc.

Phase 3 Active not recruiting
461 enrolled
Gastrointestinal

Colonic Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT05722327 2026-03-04

Phase I Trial of Adagrasib (MRTX849) in Combination With Cetuximab and Irinotecan in Patients With Colorectal Cancer

M.D. Anderson Cancer Center

Phase 1 Active not recruiting
24 enrolled
Gastrointestinal

Colonic Neoplasms, Colorectal Neoplasms

NCT05578092 2026-02-19

A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

Mirati Therapeutics Inc.

Phase 1 Terminated
64 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Colorectal Neoplasms

NCT03785249 2025-09-30

Phase 1/2 Study of MRTX849 in Patients With Cancer Having a KRAS G12C Mutation KRYSTAL-1

Mirati Therapeutics Inc.

Phase 1/2 Active not recruiting
731 enrolled 1 FDA
Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Pancreatic Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡